News & Updates
Showing Paediatrics articles
Showing
Show Multimedia Only

Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
22 Feb 2024
byAudrey Abella
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achieving steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with uncomplicated mild-to-moderately active inflammatory bowel disease (IBD).
22 Feb 2024

Cardiovascular risks high after PCI, CABG but decrease in time
10 Feb 2024
Early revascularization by percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), compared with a conservative (CON) strategy, may result in higher early risks but lower long-term risks of cardiovascular events in patients with stable coronary artery disease treated with an invasive (INV) strategy, a study has found.
10 Feb 2024






